IRLAB Therapeutics AB Class A

As of June 30, 2026, IRLAB Therapeutics AB Class A carries a market capitalization of 105.32M, placing it among publicly traded companies globally. Its enterprise value stands at 95.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IRLAB Therapeutics AB Class A's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, IRLAB Therapeutics AB Class A has 84.94M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, IRLAB Therapeutics AB Class A maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, IRLAB Therapeutics AB Class A's stock has declined approximately 18.98% over the past 52 weeks. The 50-day moving average sits at 1.81, while the 200-day moving average is 1.55.

As of June 30, 2026, IRLAB Therapeutics AB Class A holds 34.22M in cash and equivalents against 24.20M in total debt, resulting in a net debt position of -11.81M. Total book value stands at 97.13M, with working capital of 46.86M providing operational flexibility.

IRLAB Therapeutics AB Class A's most recent stock split took place on June 8, 2026 with a 958:979 split ratio.